https://vialase.com

ViaLase | Redefining Glaucoma TreatmentViaLase is redefining glaucoma treatment with 200+ years of combined experience creating femtosecond laser technology. Discover the new ViaLuxe Laser System.ViaLase | Redefining Glaucoma Treatment About Technology News Contact AT VIALASE®, WE'RE FUELING THE PRACTICE OF NONINVASIVE INTERVENTIONAL GLAUCOMA With 200 years of combined experience developing femtosecond laser technology, the ViaLase team is singularly focused on changing the way glaucoma is managed. About Us The current glaucoma treatment landscape is ripe for disruption Topical Medication High noncompliance rates and nonadherence contribute to disease progression.1 Selective Laser Trabeculoplasty (SLT) High failure rates ranging from non effective (~33% of patients) to moderately effective (short duration of ~1 year); with effectiveness decreasing over time.2 Minimally-Invasive Glaucoma Surgery (MIGS) All MIGS procedures are invasive, by definition, and most commonly performed during cataract surgery. This has limited widespread adoption and restricted patient access. Filtration Surgery Highly invasive/last resort procedure is complicated and has a failure rate of ~50% at 5 years.3 Introducing the ViaLuxe™ Laser System Designed to reduce IOP using femtosecond laser precision and micron-accurate image guidance to noninvasively create a customized drainage channel through the trabecular meshwork. Technology SEE BETTERTREAT BETTER About Our Technology Unmatched Visualization & Treatment Validation Proprietary, HD imaging capabilities overcome traditional gonioscopy limitations with uniform illumination of the angle which enables undistorted, wide field-of-view visualization. Noninvasive, Non-incisional Treatment The non-incisional approach of FLigHT may allow surgeons to deliver results similar to OR-based interventions, without opening the eye and thus, eliminating vision-threatening complications associated with surgery. Improved Patient Experience Rapid recovery results in minimal disruption in the patient’s quality of life with immediate resumption of daily activities. Potential reduction in medication burden also provides benefit by alleviating patient noncompliance and improves quality of life. Performed as a Standalone Procedure Increases patient access to an effective primary open-angle glaucoma (POAG) treatment. References: 1. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005 Oct;140(4):598-606. 2. Khawaja AP, Campbell JH, Kirby N, Chandwani HS, Keyzor I, Parekh M, McNaught AI; UK Glaucoma Real-World Data Consortium. Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom. Ophthalmology. 2020 Jun;127(6):748-757 3. Jampel HD, Musch DC, Gillespie BW, et al; Collaborative Initial Glaucoma Treatment Study Group. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005;140:16-22. Contact Us [email protected] About Technology News Contact Us Patents ViaLase, Inc. is a globally minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. Copyright © 2024 ViaLase, Inc. All Rights Reserved. | Privacy Policy ViaLase® products are currently not for sale, pending regulatory clearance. I Understand Select Your Region United States International Skip to contentenusen-UShttps://vialase.com

تعديل موقعك؟

ماذا تفعل؟